Search
Pranlukast
go.drugbank.com/drugs/DB01411InvestigationalIt antagonizes or reduces bronchospasm caused, principally in asthmatics, by an allergic reaction to accidentally or inadvertently encountered allergens.
Categories: Drugs for Obstructive Airway DiseasesProducts: PRANLUX 100 MG SAŞE, 30 SAŞE, PRANLUX 100 MG SAŞE, 90 SAŞESodium glycerophosphate
go.drugbank.com/drugs/DB09561ApprovedIt is used clinically to treat or prevent low phosphate levels [FDA Label]. Glycerophosphate is hydrolyzed to inorganic phosphate and glycerol in the body [A32667].
Mixtures: OLIMEL N7E, emulsion for infusion, OLIMEL N9E, emulsion for infusionProducts: GLYCOPHOS CONCENTRATE FOR SOLUTION FOR INFUSION 216 mg/ml, Glycophos Concentrate for Solution for Infusion 216mg/mlFerrous sulfate anhydrous
go.drugbank.com/drugs/DB13257ApprovedInvestigationalIt is the gold standard of oral iron therapy in the UK and many other countries.[L2234,L2246]
Mixtures: TL-Fol 500, TARDYFERON FOLInternational brands: Vitafer-FolAnifrolumab
go.drugbank.com/drugs/DB11976ApprovedInvestigationalerythematosus, but so far only anifrolumab has been approved. … [A237054] Anifrolumab has also been investigated for the treatment of Scleroderma.[A237044] Anifrolumab was granted FDA approval on 30 July 2021.[L34929]
Products: SAPHNELO 300MG CONCENTRATE FOR SOLUTION FOR INFUSIONSodium tartrate
go.drugbank.com/drugs/DB13707ApprovedWithdrawnSodium tartrate is a disodium salt of l-( + )-tartaric acid that is identified by transparent, colorless, and odorless crystals. It is obtained as a byproduct of wine manufacturing. … Sodium tartrate is generally recognized as safe (GRAS) as a direct human food ingredient. It acts as an emulsifier and pH control agent in food products [L2590].
Categories: Drugs for ConstipationSynonyms: Tartaric acid, disodium saltBlinatumomab
go.drugbank.com/drugs/DB09052ApprovedInvestigationalIt was first approved by the FDA in December 2014 for the treatment of CD19-positive B-cell precursor acute lymphoblastic leukemia (ALL) in relapsed and refractory patients. … [L44311] Full approval for this indication was granted in June 2023.
Products: BLINCYTO POWDER FOR INFUSION 35 MCG/VIAL, BLINCYTO (Blinatumomab) for injection 35 mcg/vialEnoxaparin
go.drugbank.com/drugs/DB01225ApprovedInvestigationalInitially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection and marketed by several pharmaceutical companies.
Products: CLEXANE 6000 IU (60 mg) / 0.6 ML (PREFILLED SYRINGE FOR INJECTION), CLEXANE 4000 IU (40 mg) / 0.4 ML (PREFILLED SYRINGE FOR INJECTION)Necitumumab
go.drugbank.com/drugs/DB09559ApprovedInvestigationalWithdrawnNecitumumab is approved for use in combination with cisplatin and gemcitabine as a first-line treatment for metastatic squamous non-small cell lung cancer (NSCLC). … It functions by binding to epidermal growth factor receptor (EGFR) and prevents binding of its ligands, a process that is involved in cell proliferation, metastasis, angiogenesis, and malignant progression
Products: PORTRAZZA CONCENTRATE FOR SOLUTION FOR INFUSION 800MG/50MLCorynebacterium diphtheriae toxoid antigen (formaldehyde inactivated)
go.drugbank.com/drugs/DB10584ApprovedInvestigationalMixtures: , Suspension for Injection, ADACEL SUSPENSION FOR INJECTIONCategories: Antiinfectives for Systemic UseBimatoprost
go.drugbank.com/drugs/DB00905ApprovedInvestigationalBimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. … [L6910] It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug
Mixtures: GANFORT® UD SOLUCION OFTALMICAProducts: LUMIGAN® UD